Application of KIAA0753 protein in preparation of medicine for treating diabetic bone loss

The KIAA0753 protein promotes osteogenic differentiation and activates the hedgehog signaling pathway, which solves the problem of poor treatment of diabetic bone loss, clarifies its mechanism of action and verifies its effectiveness in diabetic cells and animal models.

CN118892533APending Publication Date: 2024-11-05CHONGQING MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410929915.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-11
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

The prior art cannot effectively treat diabetic bone loss, and the mechanism of action of the therapeutic drug is unclear and the effect is not obvious.

Method used

Using KIAA0753 protein, through overexpressing or encoding its genes, it promotes osteogenic differentiation, activates the hedgehog signaling pathway, inhibits Gli2 protein that is ubiquitinated by the high-glycemic environment, regulates the transcription of genes related to osteogenic differentiation, and improves Treatment effects of diabetic bone loss.

Benefits of technology

It significantly improved the therapeutic effect of diabetic bone loss, promoted the expression of osteogenic differentiation marker proteins OCN and OPN, clarified the therapeutic mechanism of KIAA0753 protein, reconstructed the prokaryotic expression vector to obtain high-yield proteins, and used in diabetic cell and animal experiments. Its effectiveness in a diabetic environment was verified.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118892533A_ABST
    Figure CN118892533A_ABST
Patent Text Reader

Abstract

The invention discloses application of KIAA0753 protein in preparation of a medicine for treating diabetic bone loss, the KIAA0753 protein has a remarkable treatment effect on diabetic bone loss, and expression of marker proteins OCN and OPN for osteogenic differentiation is promoted. According to the application, the action mechanism of the KIAA0753 protein for treating the diabetic bone loss is defined, the KIAA0753 protein is located at the top end of original cilia of osteoblasts, prolongs the original cilia of the osteoblasts and activates a hedgehog signal channel, the KIAA0753 protein interacts with Gli2, SHH and OCN proteins, the KIAA0753 protein inhibits the Gli2 protein ubiquitinated by a high-glucose environment, ubiquitination of Gli2 transcription factors is reduced, and the effect of treating the diabetic bone loss is achieved. Therefore, transcription of OCN and OPN related genes for osteogenic differentiation is regulated and controlled, and osteogenic differentiation is promoted.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine and provides application of KIAA0753 protein in preparing a drug for treating diabetic bone loss. Background Art

[0002] With the rapid economic development and the improvement of people's living standards, the incidence of diabetes has increased. Because diabetes causes complications, such as diabetic retinopathy, diabetic foot, diabetic nephropathy and diabetic bone loss. Among them, diabetic bone loss is a chronic bone metabolic disease induced by diabetes, characterized by loose teeth, decreased occlusal force, decreased bone mass, increased bone brittleness, decreased strength and easy fracture. Diabetic bone loss seriously affects the quality of life of diabetic patients and brings a heavy economic burden to families and society. Therefore, in-depth exploration of therapeutic drugs for diabetic bone loss is of great significance for the treatment of diabetic bone loss.

[0003] Literature reports that patients with diabetes have bone loss, and its occurrence is mainly related to bone metabolism. At present, diabetes may affect bone metabolism through the following mechanisms: ① Long-term hyperglycemia inhibits osteoblast proliferation and differentiation and enhances osteoclast activity. ② Microvascular disease reduces bone blood supply, damages bone microstructure, and reduces bone density. ③ Accumulation of advanced glycation end products (AGEs) reduces osteoblast proliferation and promotes osteoclast differentiation. ④ Insulin resistance causes osteoblast differentiation disorders and blocks osteocalcin synthesis. ⑤ Diabetic patients have lipid metabolism disorders, increased bone marrow adipocytes, mesenchymal stem cells enhance adipose differentiation and inhibit osteogenic differentiation, and adipocytes secrete cytokines that affect osteoblasts and osteoclasts. ⑥ Diabetic nephropathy affects calcium and phosphorus metabolism, and the endocrine hormones (such as leptin, islet amylin, and bone formation inhibitory glycoprotein) caused by diabetes and the cytokines released affect the proliferation and differentiation of osteoblasts and osteoclasts. Despite the above research progress, the pathogenesis of diabetic bone loss is still unclear.

[0004] Currently, the drugs being studied for the treatment of diabetic bone loss include the traditional Chinese medicine components of Rehmannia root, Rhodiola rosea extract, the Chinese patent medicine Qiangguning, Polygonatum sibiricum polysaccharide, triterpenoid saponins extracted from Momordica grosvenori, Pien Tze Huang, naringin, irisin, Anemarrhena asphodeloides and Phellodendron amurense, shikonin, zoledronic acid, etc. However, the therapeutic mechanisms of these drugs are unclear, their effects are broad, and their results are not obvious. Summary of the invention

[0005] In view of this, the object of the present invention is to provide the use of KIAA0753 protein in the preparation of a drug for treating diabetic bone loss.

[0006] To achieve the above object, the present invention provides the following technical solutions:

[0007] 1. Use of KIAA0753 protein in preparing a drug for treating diabetic bone loss. The amino acid sequence of KIAA0753 protein is shown in SEQ ID NO.1.

[0008] 2. Use of an agent for overexpressing KIAA0753 protein, a pharmaceutical composition or a preparation containing the agent in the preparation of a drug for treating diabetic bone loss. The amino acid sequence of the KIAA0753 protein is shown in SEQ ID NO.1.

[0009] 3. Use of a gene encoding KIAA0753 protein in the preparation of a drug for treating diabetic bone loss, the nucleotide sequence of the gene is shown in SEQ ID NO.2.

[0010] 4. Use of an agonist of the aforementioned gene, a pharmaceutical composition or a preparation containing the agonist in the preparation of a drug for treating diabetic bone loss. The nucleotide sequence of the gene is shown in SEQ ID NO.2.

[0011] 5. A drug for treating diabetic bone loss, wherein the active ingredient is a reagent that overexpresses KIAA0753 protein.

[0012] 6. A drug for treating diabetic bone loss, wherein the active ingredient is an agonist of the gene encoding the KIAA0753 protein.

[0013] As one of the preferred technical solutions, the diabetic bone loss includes but is not limited to: bone loss, decreased bone density, increased risk of fractures, loose teeth, decreased bite force, decreased bone mass, increased bone brittleness, decreased bone strength and easy fractures.

[0014] The beneficial effects of the present invention are:

[0015] The KIAA0753 protein has a significant therapeutic effect on treating diabetic bone loss and promotes the expression of osteogenic differentiation marker proteins OCN and OPN. The present invention clarifies the mechanism of action of the KIAA0753 protein in treating diabetic bone loss. The KIAA0753 protein is located at the top of the primary cilia of osteoblasts, extends the primary cilia of osteoblasts, activates the hedgehog signaling pathway, and interacts with Gli2, SHH and OCN proteins. The KIAA0753 protein inhibits the ubiquitination of Gli2 proteins in a high-sugar environment and reduces the ubiquitination of Gli2 transcription factors, thereby regulating the transcription of osteogenic differentiation-related genes OCN and OPN and promoting osteogenic differentiation.

[0016] The amount of protein expressed by the prokaryotic expression vector constructed by the prior art is too small. In order to obtain a high yield of KIAA0753 protein, this application reconstructs the prokaryotic expression vector for subsequent diabetic cell experiments and diabetic animal experiments. Obtain human KIAA0753 (NM_014804) cDNA clone, PET32a prokaryotic expression vector, design restriction sites (HindⅢ, BamHI), use DNA ligase, design upstream and downstream primers, connect the PCR product into the PET32a prokaryotic expression vector, transform DH5a Escherichia coli, extract the plasmid, sequence correctly, and transform the plasmid into BL-21 Escherichia coli to express KIAA0753 protein and purify the protein.

[0017] Other advantages, objectives and features of the present invention will be described in the following description to some extent, and to some extent, will be obvious to those skilled in the art based on the following examination and study, or can be taught from the practice of the present invention. The objectives and other advantages of the present invention can be realized and obtained through the following description. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] In order to make the purpose, technical solutions and advantages of the present invention more clear, the present invention will be described in detail below in conjunction with the accompanying drawings, wherein:

[0019] Figure 1 The transcriptome sequencing results of the diabetic cell model, where A is the volcano map of the gene and B is the heat map of the gene.

[0020] Figure 2 The expression of KIAA0753 protein was significantly reduced under high glucose conditions in vitro and in vivo; Figure A is the western blot result of KIAA0753 cell protein detection, B is the statistical analysis of Figure A, C is STZ-induced diabetic mice, femur protein was extracted, and the western-blot test results showed that the expression of KIAA0753 protein in the femur of diabetic mice was significantly lower than that in the femur of normal control mice, and D is the statistical analysis of Figure C.

[0021] Figure 3 Figure 2 Effects of different glucose concentrations and different time gradients of normal glucose and high glucose on the expression of KIAA0753 protein. The cells are osteoblast precursor cells MC3T3-E1; a is Western blot detection of KIAA0753 protein expression in osteoblasts under different glucose concentrations; b is quantitative analysis of the expression level of KIAA0753 in osteoblasts under different glucose concentrations (n=3, * p<0.05, ****p<0.0001); c is the expression of KIAA0753 protein in osteoblasts under different time gradients of normal glucose and 25 mM high glucose conditions detected by Western blot; d is the quantitative analysis of the expression level of KIAA0753 in osteoblasts under different time gradients of normal glucose and 25 mM high glucose conditions (n=3, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001).

[0022] Figure 4 KIAA0753 rescues osteoblast differentiation inhibited by high glucose; A is the normal operation of the eukaryotic expression vector plasmid transfection system; B is the statistical analysis of the data in Figure A; C is the overexpression of KIAA0753 can restore the expression of KIAA0753 protein inhibited by high glucose; D is the statistical analysis of the data in Figure C; E is the activity determination of ALP enzyme, which is very important for determining osteoblast differentiation. High glucose inhibits ALP, and overexpression of KIAA0753 can restore the inhibitory effect of high glucose on ALP; F is the marker proteins OCN, OPN, ALP that inhibit osteoblast differentiation by high glucose, and overexpression of KIAA0753 can restore the inhibitory effect of high glucose on OCN, OPN, ALP proteins; G is the statistical analysis of the data in Figure F.

[0023] Figure 5 The prokaryotic expression of KIAA0753 was successful; among them, 1 is the control vector PET32a, 2 is PET32a-KIAA0753 transformed into Escherichia coli BL-21, induced by ITPG, gel electrophoresis, and Coomassie Brilliant Blue staining. An obvious protein band can be seen in lane 2, indicated by a red arrow, which is greater than 100KD, confirming that the KIAA0753 protein was successfully expressed in the prokaryotic cell.

[0024] Figure 6 The expression of KIAA0753 in femoral tissue, wherein A: western-blot; B: statistics of Figure A.

[0025] Figure 7 To confirm that KIAA0753 protein is localized at the tip of the primary cilia of osteoblasts.

[0026] Figure 8 To confirm that high glucose environment inhibits the growth of osteoblastic cilia, A is a cell immunofluorescence experiment, and B is a quantitative analysis of the fluorescence intensity of Figure A.

[0027] Fig. 9To confirm that overexpression of KIAA0753 reverses the high glucose-inhibited growth of osteoblastic cilia. A shows MC3T3-E1 cells treated with three conditions, and cilia-related protein antibodies were used for cell immunofluorescence staining; B shows the quantitative analysis of the fluorescence intensity of Figure A.

[0028] Fig.10 To confirm that high glucose inhibits the related marker proteins of the hedgehog signaling pathway, KIAA0753 was overexpressed to reverse the related marker proteins of the hedgehog signaling pathway inhibited by high glucose. A shows the cells MC3T3-E1 treated with three conditions, cell proteins were extracted, and three antibodies were used for western blot; B shows the statistical analysis of Figure A.

[0029] Fig.11 The KIAA0753 protein interacts with SHH, Gli2 and OCN proteins. A shows that HEK-293 cells were treated as shown in the figure, and the KIAA0753 protein interacted with the Gli2 protein by immunoprecipitation; B shows that HEK-293 cells were treated as shown in the figure, and the KIAA0753 protein interacted with the SHH protein by immunoprecipitation; C shows that HEK-293 cells were treated as shown in the figure, and the KIAA0753 protein did not interact with the vinculin protein by immunoprecipitation; D shows that HEK-293 cells were treated as shown in the figure, and the KIAA0753 protein interacted with the OCN protein by immunoprecipitation.

[0030] Fig.12 The relationship between high sugar and ubiquitination. A is the treatment of MC3T3-E1 cells as shown in the figure, extracting cell proteins, and performing western blot with ubiquitination antibodies; B is the statistical analysis of Figure A; C is the treatment of MC3T3-E1 cells as shown in the figure, extracting cell proteins, and performing western blot with ubiquitination antibodies; D is the statistical analysis of Figure C; E is the treatment of MC3T3-E1 cells as shown in the figure, extracting cell proteins, and performing western blot with ubiquitination antibodies; F is the statistical analysis of Figure E.

[0031] Fig.13 KIAA0753 inhibits the ubiquitination and degradation of Gli2 protein. DETAILED DESCRIPTION

[0032] The present invention will be further described below in conjunction with specific implementation modes.

[0033] MC3T3-E1 cells were purchased from Shanghai Institute of Biochemistry and Cell Biology, treated with normal glucose 5mmol / l and high glucose 25mmol / l, and the mRNA of the cells was collected and processed with Trizol kit, and sent to Wuhan Fraser Gene RNA sample sequencing;

[0034] 1. Transcriptome sequencing of diabetic cell model showed that the mRNA of MC3T3-E1 mouse osteoblast precursor cells was collected after treatment with high blood sugar (25mmol / l) at normal level. The transcriptome sequencing results showed that the transcription level of KIAA0753 in MC3T3-E1 cells treated with high blood sugar (25mmol / l) was significantly lower than that in the control group; see Figure 1 result.

[0035] 2. MC3T3-E1 cells were treated with normal glucose 5mmol / l and high blood glucose 25mmol / l, and cell proteins were extracted for western blot sample preparation using antibodies KIAA0753 rabbit anti-KIAA0753 antibody Invitrogen (USA) and GAPDH. 8-week-old SD rats were purchased from the animal room of Chongqing Medical University. Streptozotocin (STZ) (Shanghai Shenggong) was dissolved in sodium citrate buffer (50mM, pH=4.5) with a final concentration of 100mg / mL. STZ (1mL / kg) was injected intramuscularly in the diabetic group, and the control group was injected with the same dose of sodium chloride. One week later, blood glucose was measured to be greater than 250mg / dL (13.89mmol / L). After 90 days, the rats were anesthetized and killed, and the tibia of the rats was extracted for protein. Western blot was performed using antibodies KIAA0753 rabbit anti-KIAA0753 antibody Invitrogen (USA) and GAPDH. The results of western-blot of proteins in the diabetic cell model also showed that the expression of protein KIAA0753 was lower than that in the normal control group; the results of western-blot of femoral protein in the diabetic mouse animal model showed that the expression of femoral protein KIAA0753 in diabetic mice was lower than that in the control group.

[0036] Depend on Figure 2 It can be seen that both cell experiments and animal models have confirmed that diabetes reduces the expression of KIAA0753 protein, which inhibits osteogenesis.

[0037] 3. The diabetic cell model showed that high glucose inhibited KIAA0753 protein expression in a time-dependent and concentration-dependent manner. Figure 3 .

[0038] 4. The three groups of MC3T3 cells were treated as follows: 5mmol / l, high blood sugar 25mmol / l, high blood sugar 25mmol / l + overexpression of KIAA0753 plasmid; the three groups of proteins were extracted from the cells for western-blot, and it was found that overexpression of KIAA0753 reversed the inhibition of osteogenic differentiation by high glucose. The results are shown in Figure 4 .

[0039] 5. Human KIAA0753 (NM_014804) cDNA cloning (Ubao Company, Changsha, Hunan, China, Building 6, International Enterprise Center, No. 188, Huanbao Middle Road, Yuhua District, Changsha, Hunan Province), PET32a prokaryotic expression vector, design restriction sites (HindⅢ, BamHI), use DNA ligase, design upstream and downstream primers (upstream primer: 5'-ATGGGACCAGGCCA-3'; downstream primer: 5'-ttatgtagcagcctctaag-3'), connect the PCR product into the PET32a prokaryotic expression vector, transform into DH5α Escherichia coli, extract the plasmid, sequence correctly, and transform the plasmid into BL-21 Escherichia coli to express KIAA0753 protein, and purify the protein. Successful prokaryotic expression of KIAA0753 protein ( Figure 5 ).

[0040] In order to further study the specific expression pattern of KIAA0753, the applicant identified the expression of KIAA0753 protein in 13 different tissues of SD rats. The results showed that KIAA0753 protein was highly expressed in the lungs and intestines of rats, moderately expressed in the heart, stomach, kidney, spleen, liver, femur, skin, and testicles, slightly lower in the brain and eyes, and lowest in the muscles. ( Figure 6 )

[0041] In order to determine the localization of KIAA0753 in the primary cilia of MC3T3-E1 cells, the applicant conducted a cell immunofluorescence experiment. The results showed that the KIAA0753 protein was co-localized only with the ARL13B protein (ciliary long axis protein), but not with γ-tubulin (ciliary matrix protein), indicating that KIAA0753 was only specifically distributed along the long axis of the primary cilia, but not in the matrix. ( Figure 7 )

[0042] The morphology of the primary cilia of MC3T3-E1 cells induced by high glucose was detected by cell immunofluorescence experiment. The results showed that compared with the NC group, the fluorescence intensity of the cilia in the HG group was reduced and the length of the primary cilia was shortened. The above results indicate that diabetes may inhibit osteoblast differentiation and mineralization by affecting the biosynthesis of primary cilia. Figure 8 )

[0043] The morphology of the primary cilia of MC3T3-E1 cells transfected with pcDNA3.1-KIAA0753-Flag plasmid under high glucose was detected by cell immunofluorescence experiment. The results showed that overexpression of KIAA0753 under high glucose conditions significantly promoted the growth of primary cilia and increased the length of primary cilia. ( Fig. 9 )

[0044] The applicant further tested the effect of overexpression of KIAA0753 on the expression of proteins related to the Hh signaling pathway. The results showed that KIAA0753 alleviated the inhibitory effect of high glucose on Hh signaling, promoted the expression of SHH and Gli2 proteins, and inhibited the expression of SuFu protein. Fig.10 )

[0045] To further elucidate the regulatory mechanism of KIAA0753 on the Hh signaling pathway, co-immunoprecipitation (Co-IP) experiments were performed in HEK293T cells. The results showed that KIAA0753 interacted with both Gli2 and SHH ( Fig.11 A, B), and no interaction with Vinculin (a cytoplasmic actin) ( Fig.11 C). The above indicates that KIAA0753 directly regulates the Hh signaling pathway by specifically interacting with Gli2 and SHH. In addition, the applicant found that KIAA0753 also interacts with OCN protein ( Fig.11 Based on these data, the applicant speculates that KIAA0753 protein may activate the Hedgehog signaling pathway by forming a complex with SHH, Gli2 and OCN proteins, thereby improving diabetes-inhibited osteoblast differentiation. Fig.11 )

[0046] High glucose environment promotes the ubiquitination of osteogenic proteins, but overexpression of KIAA0753 inhibits the ubiquitination promoted by high glucose; in order to study whether there is a connection between high glucose and ubiquitination, the applicant induced MC3T3-E1 cells with high glucose and detected the total cell protein using ubiquitination antibodies. The results showed that compared with the NC group, the ubiquitination degree of MC3T3-E1 cell proteins under high glucose conditions increased significantly ( Fig.12 In A and B). To further explore whether overexpression of KIAA0753 has an effect on ubiquitination under high glucose conditions, the pcDNA3.1-KIAA0753-Flag plasmid was transfected into MC3T3-E1 cells induced by high glucose. The results showed that under high glucose conditions, KIAA0753 inhibited the ubiquitination promoted by high glucose ( Fig.12 C and D). The applicant simultaneously overexpressed KIAA0753 and induced Cyc in MC3T3-E1 cells under high glucose conditions. Interestingly, the results showed that Cyc had no significant effect on the inhibition of ubiquitination by overexpression of KIAA0753 ( Fig.12 Based on the above data, the applicant speculates that KIAA0753 significantly inhibits ubiquitination under high glucose conditions to promote osteoblast differentiation, but the ubiquitination process may be regulated by other signaling pathways.

[0047] Since KIAA0753 interacts with Gli2 protein, it is not clear whether KIAA0753 plays a role in the degradation of Gli2 protein. Therefore, Co-IP experiments were used to analyze their association, and MC3T3-E1 cells were transfected with pcDNA3.1-KIAA0753-Flag under normal conditions and induced by high glucose to detect the degradation of Gli2 protein. The results showed that compared with the NC group, high glucose promoted the ubiquitination of Gli2 protein, while overexpression of KIAA0753 reduced the ubiquitination of Gli2 protein. The above results indicate that KIAA0753 inhibits the ubiquitination of Gli2 protein promoted by high glucose. Based on the above data, the applicant speculates that Gli2 activates the transcription of OCN as a transcription factor, thereby upregulating OCN protein levels and promoting osteoblast differentiation. Therefore, the key core transcription factor Gli2 of the hedgehog signaling pathway is inhibited by the overexpression of KIAA0753 protein, which inhibits the ubiquitination and degradation of Gli2 protein, resulting in an increase in Gli2 protein and activation of the transcription of key genes for osteogenic differentiation such as OCN and OPN. Osteogenic differentiation is thus enhanced, thereby achieving the purpose of treating diabetic bone loss. ( Fig.13 )

[0048] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution, which should be included in the scope of the claims of the present invention.

Claims

1. The use of KIAA0753 protein in the preparation of a drug for treating diabetic bone loss, characterized in that: The amino acid sequence of KIAA0753 protein is shown in SEQ ID NO.

1.

2. Use of an agent for overexpressing KIAA0753 protein, a pharmaceutical composition or a preparation containing the agent in the preparation of a drug for treating diabetic bone loss, characterized in that: The amino acid sequence of KIAA0753 protein is shown in SEQ ID NO.

1.

3. Use of a gene encoding KIAA0753 protein in the preparation of a drug for treating diabetic bone loss, characterized in that: The nucleotide sequence of the gene is shown in SEQ ID NO.

2.

4. Use of the aforementioned gene agonist, a pharmaceutical composition or a preparation containing the agonist in the preparation of a drug for treating diabetic bone loss, characterized in that: The nucleotide sequence of the gene is shown in SEQ ID NO.

2.

5. A drug for treating diabetic bone loss, characterized in that: The active ingredient is a reagent for overexpressing KIAA0753 protein.

6. A drug for treating diabetic bone loss, characterized in that: The active ingredient is an agonist of the gene encoding the KIAA0753 protein.